“Today, the Trump Administration through the Centers for Medicare & Medicaid Services (CMS) proposed changes to the Medicare payment rules for Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS), End-Stage Renal Disease (ESRD) Prospective Payment System (PPS), and the ESRD Quality Incentive Program (QIP). Following President Trump’s recent Executive Order on Advancing American Kidney Health, the changes proposed in the rule would strengthen Medicare by improving kidney care and promoting competition in DME by modernizing the way CMS pays for care, reducing regulatory barriers for new treatments and streamlining processes…
“This proposed rule announced today includes proposals to better recognize costs for new therapies under the ESRD prospective payment system (PPS) that will spur more innovation in kidney care. CMS is proposing that certain new and innovative equipment and supplies used to care for an ESRD patient would qualify for an add-on payment adjustment. This proposed change would create incentives for ESRD facilities to provide the latest therapies that will improve health outcomes.”
“In this rule, CMS is proposing refinements to eligibility for the transitional drug add-on payment adjustment (TDAPA) under the ESRD PPS to better target the additional payment to innovative renal dialysis drugs and biological products based on the Food and Drug Administration’s (FDA’s) New Drug Application Classifications. CMS is also proposing to exclude generic drugs from TDAPA eligibility so that research can be targeted to new and innovative drugs for patients with ESRD…” Read the full post here.
Source: New CMS Proposals Strengthen Medicare, Unleash Innovation and Promote Competition to Provide Kidney Patients with Better Value and Results – July 29, 2019. CMS.gov.
